Cargando…
SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770899/ http://dx.doi.org/10.1053/j.gastro.2021.12.029 |
| _version_ | 1784635474747326464 |
|---|---|
| author | Khan, Muhammad Mushtaq, Kamran Saddique, Muhammad Alghizzawi, Mohd Yasir, Muhammad Younis, Hafiz Rashid, Farah AlSoub, Deema Yakoob, Rafie AlKaabi, Saad Al-Ejji, Khalid |
| author_facet | Khan, Muhammad Mushtaq, Kamran Saddique, Muhammad Alghizzawi, Mohd Yasir, Muhammad Younis, Hafiz Rashid, Farah AlSoub, Deema Yakoob, Rafie AlKaabi, Saad Al-Ejji, Khalid |
| author_sort | Khan, Muhammad |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8770899 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87708992022-01-20 SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE Khan, Muhammad Mushtaq, Kamran Saddique, Muhammad Alghizzawi, Mohd Yasir, Muhammad Younis, Hafiz Rashid, Farah AlSoub, Deema Yakoob, Rafie AlKaabi, Saad Al-Ejji, Khalid Gastroenterology Comparative Effectiveness Studies Published by Elsevier Inc. 2022-02 2022-01-20 /pmc/articles/PMC8770899/ http://dx.doi.org/10.1053/j.gastro.2021.12.029 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Comparative Effectiveness Studies Khan, Muhammad Mushtaq, Kamran Saddique, Muhammad Alghizzawi, Mohd Yasir, Muhammad Younis, Hafiz Rashid, Farah AlSoub, Deema Yakoob, Rafie AlKaabi, Saad Al-Ejji, Khalid SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| title | SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| title_full | SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| title_fullStr | SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| title_full_unstemmed | SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| title_short | SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE |
| title_sort | safety and effectiveness of the bnt162b2 mrna covid-19 vaccine in a nationwide cohort of patients with inflammatory bowel disease |
| topic | Comparative Effectiveness Studies |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770899/ http://dx.doi.org/10.1053/j.gastro.2021.12.029 |
| work_keys_str_mv | AT khanmuhammad safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT mushtaqkamran safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT saddiquemuhammad safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT alghizzawimohd safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT yasirmuhammad safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT younishafiz safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT rashidfarah safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT alsoubdeema safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT yakoobrafie safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT alkaabisaad safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease AT alejjikhalid safetyandeffectivenessofthebnt162b2mrnacovid19vaccineinanationwidecohortofpatientswithinflammatoryboweldisease |